A Study to Evaluate VXA-CoV2-3.1 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

Phase 2

Recruiting

Conditions: SARS-CoV2
COVID-19

Interventions: Biological: VXA-CoV2-3.1
Biological: COMIRNATY®

Registration Number: NCT06672055

Lead Sponsor: Vaxart

Brief Summary: The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.1 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19).

Detailed Description: Not available

Recruitment & Eligibility

Status: RECRUITING

Sex: All

Target Recruitment: 10000

Inclusion Criteria

Adults 18 years of age and above, at time of screening.
Completed primary approved/authorized COVID-19 vaccination series with ≥ 2 mRNA vaccine doses.
Last COVID-19 vaccine received ≥6 months prior to study vaccination.
Male and female participants of childbearing potential must agree to consistently use a highly effective method of contraception from at least 30 days prior to enrollment and through 3 months after the last study vaccination.
Is medically stable, as determined by the site investigator (based on review of health status, vital signs, medical history, and physical examination) with screening lab values within normal limits or abnormalities assessed as not clinically significant.
Agree to not participate in any other SARS-CoV-2 infection prevention trial (vaccine, drug, biologic, PrEP) during participation in the study.
Willing and able to provide informed consent prior to initiation of study procedures.
Available for all study visits, willing to participate in all study procedures, and not planning to relocate from the area for the duration of the study.
Negative rapid molecular Covid test at the screening visit and on Day 1 prior to vaccine dosing.

Exclusion Criteria

Participant has an acute illness as defined by any of the following (note: assessment may be repeated once during screening period):

a. As determined by the site investigator, within 72 hours prior to vaccination.

i. An acute illness that is nearly resolved, with only minor residual symptoms remaining, is allowable if, in the opinion of the site investigator, the residual symptoms will not interfere with the ability of study staff to assess safety parameters as required by the protocol. b. Presence of a fever ≥ 38.0°C (100.4°F) measured orally at baseline, on Day 1 prior to vaccination. c. Receipt of antipyretic/analgesic medications within 24 hours prior to vaccine administration.
Participant has had a positive COVID test within 90 days prior to screening.
Current or planned participation in any other interventional clinical trial.
Participation in research involving any investigational product within 45 days prior to study vaccination.
Receipt of any approved or authorized products intended to prevent SARS-CoV2 infection within 6 months prior to study vaccination.
Receipt or donation of blood products or immunoglobulins within 60 days prior to enrollment or planned administration during the study.
Received influenza vaccination within 14 days prior to study vaccination, or any other vaccine within 30 days prior to study vaccination.
Any autoimmune or immunodeficiency disease/condition (including and not limited to untreated or advanced HIV infection with CD4 counts <200 cells/mm^3, history of AIDS defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV, severe combined immunodeficiency (SCID), hypogammaglobulinemia, asplenia or functional asplenia).
Unstable medical or psychiatric illness (acute or chronic illness) requiring significant medical monitoring and intervention during the 90 days prior to enrollment. Note: diabetes mellitus (Types 1 & 2) are not excluded if assessed by the principal investigator (PI) as well-controlled.
Administration of immunosuppressants, systemic glucocorticoids, or other immune-modifying drugs within the following timeframes:
1. B-cell therapies within the 6 months prior to first study vaccination
2. Prednisone, ≥20 mg for more than 2 weeks, within the 30 days prior to study vaccination
3. Other medications in this category, including but not limited to high-dose inhaled corticosteroids (>800 mcg/day of beclomethasone dipropionate or equivalent); antimetabolites; transplant immunosuppressive agents; alkylating agents; cell-depleting agents; or cancer chemotherapeutics, within the 90 days prior to study vaccination.
4. Any medication for any period of time that, in the opinion of the site investigator, could impede immune response to vaccination.
5. Use of any dose montelukast OR inhaled, intranasal, intra-articular, or systemic corticosteroids within 2 weeks prior to study vaccination.
6. Planned use of any of these medications during the study.
Known contraindication to IM injection or blood draws (e.g. bleeding diathesis, acquired coagulopathy, significant bleeding or bruising) or to oral route of administration (unable to swallow tablets).
Any known allergies to components contained in the investigational product (including fish gelatin) or comparator or latex allergy (including polyethylene glycol [PEG] allergies) and/or history of serious reactions to vaccination such as anaphylaxis, respiratory problems, hives, or abdominal pain.
Women who are pregnant (pregnancy tests will be performed at screening and prior to dosing), breastfeeding, or who plan to become pregnant during the study.
History of irritable bowel disease or other inflammatory digestive or gastrointestinal condition that could affect the distribution/safety evaluation of an orally administered vaccine targeting the mucosa of the small intestine. Such conditions may include but are not limited to:

a. Any history of: i. GI malignancy ii. malabsorption iii. pancreatobiliary disorders iv. inflammatory bowel disease v. irritable bowel disease vi. hiatal hernia vii. surgical resection b. History of diagnosis or treatment in past 5 years of: i. esophageal or gastric motility disorder ii. gastroesophageal reflux disorder iii. peptic ulcer iv. cholecystectomy.
Use of antibiotics, proton pump inhibitors, H2 blockers, or antacids within 7 days prior to study drug administration or planned use during the study.
Use of drugs known to affect gastrointestinal motility including glucagon-like peptide 1 (GLP-1) receptor agonists including tirzepatide (Mounjaro) and semaglutide (Wegovy, Ozempic) within 30 days prior to drug administration.
Daily use of nonsteroidal anti-inflammatory drugs within 7 days prior to study drug administration or planned use during the study.
Personal or familial history of hypercoagulable states to include personal past history of deep vein thrombosis (DVT).
Personal history of myocarditis or pericarditis.
Positive Hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody at the screening visit.
History of drug, alcohol, or chemical abuse within 1 year of screening.
Positive urine drug screen for drugs of abuse at screening (except for previous marijuana use); concurrent or planned use of marijuana during the active study period are excluded. Positive urine drug screen (UDS) at screening due to prescribed stimulants will be reviewed on a case by case basis.
Cancer, or treatment for cancer, within the past 3 years (excluding fully treated and resolved basal cell carcinoma or squamous cell carcinoma).
History of any form of angioedema.
History of GI bleeding including hematochezia (blood in stool) or melena (black stool) of unknown etiology or that has not been evaluated.
Any history or conditions that may lead to a higher risk of clotting events and/or thrombocytopenia, including:
1. Familial coagulopathy or personal history of bleeding disorder or thrombosis
2. History of heparin-related thrombotic events, and/or receiving heparin treatments
3. History of autoimmune or inflammatory disease
4. Presence of any of the following conditions known to increase the risk of thrombosis within 6 months prior to screening:
i. Recent surgery other than fully healed cesarean delivery or excision/ biopsy of cutaneous lesions ii. Immobility (confined to bed or wheelchair for 3 or more successive days) iii. Head trauma with loss of consciousness or documented brain injury iv. Receipt of anticoagulants for prophylaxis of thrombosis v. Recent clinically significant infection including hospitalization for COVID-19 related illness.
Any other condition that, in the opinion of the investigator, would pose a health risk to the participant if enrolled or could interfere with evaluation of the investigational product or interpretation of study results.
Study team member or first-degree relative of any study team member (inclusive of sponsor and site personnel involved in the study).

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
VXA-CoV2-3.1	VXA-CoV2-3.1	Participants previously immunized against COVID-19 infection will be randomized to receive VXA-CoV2-3.1 tablet oral vaccine.
COMIRNATY®	COMIRNATY®	Participants previously immunized against COVID-19 infection will be randomized to receive COMIRNATY® injectable COVID-19 vaccine.

Primary Outcome Measures

Name	Time	Method
Percentage of Participants with First Occurrence of Symptomatic Polymerase Chain Reaction (PCR)-Positive COVID-19 at 14 Days Post-booster Vaccination	Up to approximately Day 14
Percentage of Participants with First Occurrence of Symptomatic Polymerase Chain Reaction (PCR)-Positive COVID-19 at 12 Months Post-booster Vaccination	Up to approximately 12 months

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants with First Occurrence of Symptomatic PCR-Positive COVID-19 Within 14 Days and 12 Months Post-booster Vaccination in Participants with Specified Body Mass Index (BMI)	Up to approximately 12 months
Percentage of Participants with First Occurrence of Symptomatic PCR-Positive COVID-19 within 0 and 6 Months Post-booster Vaccination	Up to approximately 6 months
Percentage of Participants with First Occurrence of Symptomatic PCR-Positive COVID-19 within 6 and 12 Months Post-booster Vaccination	Up to approximately 12 months
Number of Participants with First Occurrence of Asymptomatic PCR-Positive COVID-19 within 14 Days and 12 Months Post-vaccination	Up to approximately 12 months
Number of Participants with First Occurrence of Severe PCR-Positive COVID-19 within 14 Days and 12 Months Post-vaccination	Up to approximately 12 months
Percentage of Participants who Experience any Solicited Local Reactogenicity Through 7 Days Post-vaccination	Up to approximately Day 7
Percentage of Participants who Experience any Solicited Systemic Reactogenicity Through 7 Days Post-vaccination	Up to approximately Day 7
Percentage of Participants who Experience Unsolicited Adverse Events (AEs) Through 30 Days Post-vaccination	Up to approximately Day 30
Percentage of Participants who Experience AEs of Special Interest (AESIs)	Up to approximately 12 months
Percentage of Participants who Experience Treatment-emergent Adverse Events (TEAEs)	Up to approximately 12 months	An AE is any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurred after the participant received study treatment. An AE of special interest (AESI) is an AE (serious or non-serious) of scientific and medical concern specific to the sponsor's product or program. Medically attended AEs (MAAEs) are defined as AEs with medically attended visits including hospital, emergency room, urgent care clinic. A serious TEAE (SAE) is any untoward medical occurrence in a clinical study participant after first dose irrespective of a causal relationship with the study treatment that resulted in death, was immediately life threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or another medically important serious event.
Percentage of Participants With any Clinically Significant Abnormal Safety Laboratory Results Within 7 Days Pots-vaccination	Up to approximately Day 7
Concentration of SARS-CoV-2 Specific Serum Neutralizing Antibodies (nAb) Post-vaccination	Day 1 and Months 1, 3, 6, and 12
Fold Rise of SARS-CoV-2 Specific Serum nAb Post-vaccination Post-vaccination	Day 1 and Months 1, 3, 6, and 12
Concentration of Serum Immunoglobulin G (IgG) Binding Antibody (bAb) Against Spike Protein (S) and Receptor Binding Domain (RBD) Post-vaccination	Day 1 and Months 1, 3, 6, and 12
Fold Rise of Serum IgG Anti-S or RBD Specific bAb Post-vaccination	Day 1 and Months 1, 3, 6, and 12
Concentration of Serum Immunoglobulin A (IgA) bAb Against S and RBD Post-vaccination	Day 1 and Months 1, 3, 6, and 12
Fold Rise of Serum IgA Anti-S or RBD Specific bAb Post-vaccination	Day 1 and Months 1, 3, 6, and 12
Concentration of S and RBD-specific Saliva IgA bAb Post-vaccination	Day 1 and Months 1, 3, 6, and 12
Fold Rise of S and RBD-specific Saliva IgA bAb Post-vaccination	Day 1 and Months 1, 3, 6, and 12
Concentration of S and RBD-specific Nasal Lining Fluid (NLF) IgA bAb Post-vaccination	Day 1 and Months 1, 3, 6, and 12
Fold Rise of S and RBD-specific NLF IgA bAb Post-vaccination	Day 1 and Months 1, 3, 6, and 12
Percentage of Participants With 2, 3, and 4 Fold Rise in S or RBD-Specific Serum IgG and IgA bAb, Serum nAb, Saliva IgA bAb, and NLF IgA bAb Post-vaccination	Day 1 and Months 1, 3, 6, and 12
Concentration of Intracellular T Cell Cytokine and Cell Surface Marker 1 Month Post-vaccination	Day 1 and Month 1
Concentration of Intracellular T Cell Cytokine and Cell Surface Marker Post-vaccination	Day 1 and Months 1, 3, 6, and 12

Trial Locations

Locations (145): Pinnacle Research Group
🇺🇸
Anniston, Alabama, United States
Core Clinical Trials - Central Alabama Research LLC
🇺🇸
Birmingham, Alabama, United States
Coastal Clinical Research
🇺🇸
Mobile, Alabama, United States
Avacare - Lenzmeier Family Medicine
🇺🇸
Glendale, Arizona, United States
Desert Clinical Research
🇺🇸
Mesa, Arizona, United States
Velocity Clinical Research - MedPharmics - Phoenix
🇺🇸
Phoenix, Arizona, United States
Foothills Research Center
🇺🇸
Phoenix, Arizona, United States
Avacare (CCT) - Fiel Family & Sports Medicine
🇺🇸
Tempe, Arizona, United States
Baptist Health Center for Clinical Research - Little Rock
🇺🇸
Little Rock, Arkansas, United States
Elligo Health Research (BTC/ClinEdge) - Core Healthcare Group
🇺🇸
Cerritos, California, United States
Velocity Clinical Research - Chula Vista (eStudySite - Chula Vista)
🇺🇸
Chula Vista, California, United States
Avacare - Benchmark Research - SOCAL-Colton
🇺🇸
Colton, California, United States
Altasciences Los Angeles (Formerly WCCT Global)
🇺🇸
Cypress, California, United States
Ark Clinical Research - Fountain Valley, CA
🇺🇸
Fountain Valley, California, United States
Velocity Clinical Research - San Diego (eStudySite - La Mesa)
🇺🇸
La Mesa, California, United States
Ark Clinical Research - Long Beach, CA
🇺🇸
Long Beach, California, United States
Velocity Clinical Research (National Research Institute) - Panorama City
🇺🇸
Los Angeles, California, United States
Northern California Research
🇺🇸
Sacramento, California, United States
Avacare - Benchmark Research - Sacramento
🇺🇸
Sacramento, California, United States
Velocity Clinical Research - Gardena
🇺🇸
Santa Ana, California, United States
Elite Research Network (ERN) - Legacy Clinical Trials
🇺🇸
Colorado Springs, Colorado, United States
Tekton Research - Fort Collins
🇺🇸
Fort Collins, Colorado, United States
Avacare - Critical Care, Pulmonary and Sleep Associates
🇺🇸
Lakewood, Colorado, United States
Tekton Research - Colorado - Longmont
🇺🇸
Longmont, Colorado, United States
Paradigm Clinical Research - Wheat Ridge
🇺🇸
Wheat Ridge, Colorado, United States
Stamford Therapeutics Consortium
🇺🇸
Stamford, Connecticut, United States
Chase Medical Research
🇺🇸
Waterbury, Connecticut, United States
Velocity Clinical Research - Washington DC
🇺🇸
Washington, District of Columbia, United States
AMR - Miami (Clinical Research of South Florida)
🇺🇸
Coral Gables, Florida, United States
Universal Axon Clinical Research
🇺🇸
Doral, Florida, United States
Velocity Clinical Research - New Smyrna Beach
🇺🇸
Edgewater, Florida, United States
Fleming Island Center For Clinical Research
🇺🇸
Fleming Island, Florida, United States
AMR - Fort Myers - Clinical Physiology Associates
🇺🇸
Fort Myers, Florida, United States
Velocity Clinical Research - Hallandale Beach (MD Clinical)
🇺🇸
Hallandale Beach, Florida, United States
ENCORE - Nature Coast Clinical Research Inverness
🇺🇸
Inverness, Florida, United States
ENCORE - Westside Center for Clinical Research
🇺🇸
Jacksonville, Florida, United States
Jacksonville Center for Clinical Research
🇺🇸
Jacksonville, Florida, United States
Headlands Research - JEM Research - Lake Worth
🇺🇸
Lake Worth, Florida, United States
Velocity Clinical Research - Boise (Meridian)
🇺🇸
Meridian, Idaho, United States
Accel Research Sites - Lakeland
🇺🇸
Lakeland, Florida, United States
Accel Research Sites (ARS) - St. Petersburg - Largo
🇺🇸
Largo, Florida, United States
Accel Research Sites - Maitland
🇺🇸
Maitland, Florida, United States
K2 Medical Research - Maitland
🇺🇸
Maitland, Florida, United States
SRA Trials LLC - Miami Clinical Trials at Suncoast Research Associates
🇺🇸
Miami, Florida, United States
Atlas Clinical Research - Suncoast Clinical Research - Pasco County
🇺🇸
New Port Richey, Florida, United States
Biscayne Clinical Research
🇺🇸
North Miami Beach, Florida, United States
K2 Medical Research - South Orlando
🇺🇸
Orlando, Florida, United States
Boca Raton Clinical Research (BRCR) Global - Weston
🇺🇸
Plantation, Florida, United States
ENCORE - St. Johns Center for Clinical Research
🇺🇸
Saint Augustine, Florida, United States
IMA Clinical Research - St. Petersburg
🇺🇸
Saint Petersburg, Florida, United States
hyperCORE - Centricity Research Columbus
🇺🇸
Columbus, Georgia, United States
Javara Research - Privia Medical Group Georgia
🇺🇸
Fayetteville, Georgia, United States
Privia Health - SouthCoast Health
🇺🇸
Fayetteville, Georgia, United States
Avacare (CCT) - Lifeline Primary Care
🇺🇸
Lilburn, Georgia, United States
IMA Clinical Research - Chicago
🇺🇸
Chicago, Illinois, United States
hyperCORE - Centricity Research (IACT Health) - Rincon
🇺🇸
Rincon, Georgia, United States
Velocity Clinical Research - Savannah
🇺🇸
Savannah, Georgia, United States
Accellacare - Duly Health and Care
🇺🇸
Lombard, Illinois, United States
Velocity Clinical Research - Valparaiso (Buynak Clinical Research)
🇺🇸
Valparaiso, Indiana, United States
Accellacare - McFarland Clinic
🇺🇸
Ames, Iowa, United States
Velocity (Meridian) Clinical Research - Sioux City
🇺🇸
Sioux City, Iowa, United States
AMR - El Dorado - Heartland Research Associates
🇺🇸
El Dorado, Kansas, United States
Johnson County Clin-Trials
🇺🇸
Lenexa, Kansas, United States
AMR - Newton (Heartland Research Associates)
🇺🇸
Newton, Kansas, United States
AMR - Wichita West - Heartland Research Associates
🇺🇸
Wichita, Kansas, United States
AMR - Wichita East - Heartland Research Associates
🇺🇸
Wichita, Kansas, United States
AMR - Lexington (Central Kentucky Research Associates)
🇺🇸
Lexington, Kentucky, United States
Velocity (Meridian) Clinical Research - Baton Rouge
🇺🇸
Baton Rouge, Louisiana, United States
Avacare - Benchmark Research - New Orleans-North Shore
🇺🇸
Covington, Louisiana, United States
Velocity Clinical Research - MedPharmics - Covington
🇺🇸
Covington, Louisiana, United States
Boca Raton Clinical Research (BRCR) Global USA - New Orleans
🇺🇸
Gretna, Louisiana, United States
Velocity Clinical Research - MedPharmics - Lafayette
🇺🇸
Lafayette, Louisiana, United States
Avacare - Benchmark Research - Metairie
🇺🇸
Metairie, Louisiana, United States
AMR - New Orleans - Center for Clinical Research
🇺🇸
New Orleans, Louisiana, United States
Javara Research - Privia Medical Group Mid-Atlantic - Annapolis
🇺🇸
Annapolis, Maryland, United States
Pharmaron
🇺🇸
Baltimore, Maryland, United States
Avacare (CCT) - Advanced Primary and Geriatric Care
🇺🇸
Rockville, Maryland, United States
Velocity (Meridian) Clinical Research - Rockville
🇺🇸
Rockville, Maryland, United States
Javara Research - Mankato Clinic
🇺🇸
Mankato, Minnesota, United States
Velocity Clinical Research - MedPharmics - Gulfport
🇺🇸
Gulfport, Mississippi, United States
Avacare (CCT) - Clay Platte Family Medicine Clinic
🇺🇸
Kansas City, Missouri, United States
Avacare (CCT) - Skyline Medical Center
🇺🇸
Elkhorn, Nebraska, United States
Velocity (Meridian) Clinical Research - Grand Island
🇺🇸
Grand Island, Nebraska, United States
Be Well Clinical Studies - Nebraska
🇺🇸
Lincoln, Nebraska, United States
Velocity (Meridian) Clinical Research - Omaha
🇺🇸
Omaha, Nebraska, United States
hyperCORE - ActivMed Practices and Research - Portsmouth
🇺🇸
Portsmouth, New Hampshire, United States
DM Clinical Research - Jersey City
🇺🇸
Jersey City, New Jersey, United States
Velocity Clinical Research - Alburquerque
🇺🇸
Albuquerque, New Mexico, United States
AXCES Research & Health - Santa Fe
🇺🇸
Santa Fe, New Mexico, United States
IMA Clinical Research - Albany, Suite 202
🇺🇸
Albany, New York, United States
Velocity Clinical Research - Syracuse
🇺🇸
East Syracuse, New York, United States
IMA Clinical Research - Manhattan
🇺🇸
New York, New York, United States
Atlas Clinical Research - Rochester Clinical Research
🇺🇸
Rochester, New York, United States
Cary Medical Group
🇺🇸
Cary, North Carolina, United States
Velocity Clinical Research - Durham
🇺🇸
Durham, North Carolina, United States
Accellacare - Hickory
🇺🇸
Hickory, North Carolina, United States
Accellacare - Raleigh
🇺🇸
Raleigh, North Carolina, United States
Accellacare - Rocky Mount
🇺🇸
Rocky Mount, North Carolina, United States
Accellacare - Salisbury
🇺🇸
Salisbury, North Carolina, United States
Accellacare - Piedmont Healthcare
🇺🇸
Statesville, North Carolina, United States
Accellacare - Tradd Court
🇺🇸
Wilmington, North Carolina, United States
Accellacare - Winston-Salem
🇺🇸
Winston-Salem, North Carolina, United States
Atrium Health Wake Forest Baptist - Comprehensive Cancer Center
🇺🇸
Winston-Salem, North Carolina, United States
Velocity Clinical Research - Cleveland (Rapid Medical Research)
🇺🇸
Beachwood, Ohio, United States
CTI Clinical Research Center
🇺🇸
Cincinnati, Ohio, United States
Velocity Clinical Research - Cincinnati (New Horizons Clinical Research - Blue Ash)
🇺🇸
Cincinnati, Ohio, United States
Tekton Research - Oklahoma - Magnolia Court
🇺🇸
Moore, Oklahoma, United States
Tekton Research - Delaware Pointe
🇺🇸
Tulsa, Oklahoma, United States
Tekton Research - Oklahoma - Primary Health Partners
🇺🇸
Yukon, Oklahoma, United States
Velocity Clinical Research - Grants Pass
🇺🇸
Grants Pass, Oregon, United States
Avacare (CCT) - Hatboro Medical Associates
🇺🇸
Hatboro, Pennsylvania, United States
Atlas Clinical Research - Suburban Research Associates - Media Office
🇺🇸
Media, Pennsylvania, United States
Velocity Clinical Research - Providence (East Greenwich)
🇺🇸
East Greenwich, Rhode Island, United States
Velocity Clinical Research - Anderson
🇺🇸
Anderson, South Carolina, United States
Velocity Clinical Research - Charleston
🇺🇸
Charleston, South Carolina, United States
Velocity Clinical Research - Columbia (VitaLink)
🇺🇸
Columbia, South Carolina, United States
Accellacare - Charleston
🇺🇸
Mount Pleasant, South Carolina, United States
Trial Management Associates - Myrtle Beach
🇺🇸
Myrtle Beach, South Carolina, United States
hyperCORE International - Coastal Carolina Research Center
🇺🇸
North Charleston, South Carolina, United States
IMA Clinical Research - Austin
🇺🇸
Austin, Texas, United States
Tekton Research - Austin
🇺🇸
Austin, Texas, United States
Orion Clinical Research
🇺🇸
Austin, Texas, United States
Velocity Clinical Research - Austin
🇺🇸
Austin, Texas, United States
Tekton Research - Beaumont
🇺🇸
Beaumont, Texas, United States
Velocity Clinical Research - Union (Vitalink)
🇺🇸
Union, South Carolina, United States
Accellacare - PMG Research of Bristol
🇺🇸
Bristol, Tennessee, United States
Alliance for Multispecialty Research (AMR) - Corporate
🇺🇸
Knoxville, Tennessee, United States
Accellacare of Knoxville
🇺🇸
Knoxville, Tennessee, United States
Velocity Clinical Research - Abilene
🇺🇸
Abilene, Texas, United States
PanAmerican Clinical Research - Brownsville, Levee Street
🇺🇸
Brownsville, Texas, United States
Cedar Health Research - Arlington/Euless
🇺🇸
Euless, Texas, United States
EmVenio Research - Fort Worth, TX
🇺🇸
Fort Worth, Texas, United States
Avacare - Benchmark Research Fort Worth
🇺🇸
Fort Worth, Texas, United States
DM Clinical Research - CyFair Clinical Research Center
🇺🇸
Houston, Texas, United States
Tekton Research - Fredericksburg Road
🇺🇸
San Antonio, Texas, United States
DM Clinical Research - Tomball - Multiple Specialties
🇺🇸
Tomball, Texas, United States
Velocity Clinical Research - Waco (formerly: Impact Research Institute)
🇺🇸
Waco, Texas, United States
Avacare (CCT) - Ogden Clinic - Grand View
🇺🇸
Roy, Utah, United States
Avacare (CCT) - Olympus Family Medicine
🇺🇸
Salt Lake City, Utah, United States
South Ogden Family Medicine
🇺🇸
South Ogden, Utah, United States
Health Research of Hampton Roads
🇺🇸
Newport News, Virginia, United States
AMR - Norfolk (Clinical Research Associates of Tidewater)
🇺🇸
Norfolk, Virginia, United States
Centricity Research (IACT Health) - Suffolk Primary Care
🇺🇸
Suffolk, Virginia, United States
Velocity Clinical Research - Medford
🇺🇸
Spokane, Washington, United States
Velocity Clinical Research - Spokane
🇺🇸
Spokane, Washington, United States

A Study to Evaluate VXA-CoV2-3.1 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

Recruitment & Eligibility

Study & Design

Trial Locations

Instant Trial Alerts

Instant Trial Alerts